RegulatoryOfficial
FDA approves Infilbray, first treatment for neurological symptoms of Type 3 Gaucher disease
🇺🇸 FDA · Wed 18 Nov 2026
The US regulator has cleared Sanofi unit Genzyme's venglustat tablets for adults and children weighing at least 15 kg, with psychiatric risks highlighted in the safety information.
The US Food and Drug Administration approved Infilbray (venglustat) tablets on 18 November 2026 as the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3). The indication covers adults and paediatric patients weighing at least 15 kg, roughly 33 pounds. The marketing authorisation was granted to Genzyme Corporation, a Sanofi company.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Article written by VigiEye from the official source (FDA). AI-assisted; check the source before acting.
More Regulatory
All →
EEA Joint Committee extends three EU feed additive rules to Iceland and Norway
🇪🇺 EUR-Lex · Thu 19 Nov 2026
Health Canada lists Class II recall of Stryker's Blueprint shoulder-planning software over two bugs
🇨🇦 Health Canada · Wed 18 Nov 2026
INFARMED lifts suspension of Limeciclina Atral 408 mg capsules after bioequivalence shown
🇵🇹 INFARMED · Wed 18 Nov 2026
Commission publishes minutes of SCHEER working group meeting on brain stimulators
🇪🇺 European Commission (DG SANTE) · Wed 18 Nov 2026
AIFA reminds sponsors how to pay Annual Safety Report evaluation fee
🇮🇹 AIFA · Wed 18 Nov 2026
Paul-Ehrlich-Institut Highlights Vaccines and Antibodies in Fight Against Antimicrobial Resistance
🇩🇪 Paul-Ehrlich-Institut · Wed 18 Nov 2026